Results 261 to 270 of about 618,690 (430)

Assessment of ethnic differences in pharmacokinetics and clinical responses of acalabrutinib between Chinese and White patients with B‐cell malignancies

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims The aim of this study was to assess differences between Chinese and White patients in pharmacokinetics (PK) of, and clinical response to, acalabrutinib and its pharmacologically active major metabolite, ACP‐5862, to support recommended dosing in Chinese patients with B‐cell malignancies.
Tingting Yao, Junjie Ding, Shringi Sharma, Yunfei Li, Qianwei Xu, Peiming Ma   +5 more
wiley   +1 more source

Posterior ischemic optic neuropathy following continuous renal replacement therapy: a case report. [PDF]

Int J Emerg Med
Takefuji H, Komagamine J.
europepmc   +1 more source

Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of study was to generate quantitative data on the abundance of drug‐metabolizing enzymes and transporters (DMETs) in inflamed and non‐inflamed Crohn's disease (CD) ileum and colon, for incorporation into physiologically based pharmacokinetic (PBPK) models, enabling prediction of oral drugs' pharmacokinetics (PK) perturbation in CD patients.
Sarah Alrubia, Brahim Achour, Zubida M. Al‐Majdoub, Amin Rostami‐Hodjegan, Jill Barber   +4 more
wiley   +1 more source

Role of Renal Replacement Therapy in Managing Toluene-Induced Acidosis. [PDF]

Am J Case Rep
Yoshida N, Takahashi S, Hitaka M, Ohashi Y, Ichibayashi R.   +4 more
europepmc   +1 more source

RENAL REPLACEMENT THERAPY (RRT) AND ORTHOTOPIC LIVER TRANSPLANTATION(OLTX): A NEGATIVE PREDICTOR OF SURVIVAL.

, 2000
Thomas A. Gonwa, Carlos G. Fasola, Marlon F. Levy, Robert M. Goldstein, Ernesto P. Molmenti, Göran B. Klintmalm   +5 more
openalex   +1 more source

Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, Volume 91, Issue 5, Page 1306-1321, May 2025.
Aims This review aimed to synthesise the evidence related to the incidence of serious and non‐serious adverse events with the use of monoclonal antibodies (mAbs) among COVID‐19 patients. Methods Databases were searched from January 2020 to September 2023 for randomized clinical trials (RCTs) that used mAbs for the treatment of COVID‐19 regardless of ...
Htet Htet, Han You Kyung, Ismail Abdul Sattar Burud, Heethal Jaiprakash, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal   +6 more
wiley   +1 more source

Projecting renal replacement therapy–specific end-stage renal disease prevalence using registry data

, 2000
Douglas E. Schaubel, Howard Morrison, Stanley Fenton   +2 more
openalex   +2 more sources

Patient Selection and Timing of Continuous Renal Replacement Therapy

Blood Purification, 2016
M. Ostermann, M. Joannidis, A. Pani, M. Floris, S. de Rosa, J. Kellum, C. Ronco   +6 more
semanticscholar   +1 more source

Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis

British Journal of Clinical Pharmacology, EarlyView.
Objective To determine the optimal anticoagulation intensity of warfarin in a South‐East Asian population with moderate‐to‐severe rheumatic mitral stenosis. Methods A multicentre, retrospective study examined patients with rheumatic mitral stenosis who had not undergone valve replacement or repair and required long‐term warfarin therapy at two ...
Punyawee Puchsaka, Wipharak Rattanavipanon, Sararat Phetroong, Rudeekorn Ue‐sethasakdhi, Suparat Wattanasombat, Wattana Wongtheptien, Surakit Nathisuwan   +6 more
wiley   +1 more source

Comparison of intermittent and continuous renal replacement therapy for sepsis-associated AKI: a retrospective analysis of the Japanese ICU database. [PDF]

JA Clin Rep
Okano H, Okamoto H, Tanaka H, Sakurai R, Yamazaki T.   +4 more
europepmc   +1 more source